117 related articles for article (PubMed ID: 38184237)
21. Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
Kuo EJ; Sho S; Li N; Zanocco KA; Yeh MW; Livhits MJ
JAMA Surg; 2018 Jan; 153(1):52-59. PubMed ID: 28973144
[TBL] [Abstract][Full Text] [Related]
22. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract][Full Text] [Related]
23. Predicting Outcomes in Sporadic and Hereditary Medullary Thyroid Carcinoma over Two Decades.
Kotwal A; Erickson D; Geske JR; Hay ID; Castro MR
Thyroid; 2021 Apr; 31(4):616-626. PubMed ID: 33108969
[No Abstract] [Full Text] [Related]
24. Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening.
Torresan F; Mian C; Cavedon E; Iacobone M
Langenbecks Arch Surg; 2019 Jun; 404(4):411-419. PubMed ID: 30903267
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic factors of lymph node-negative metastasis gastric cancer].
Sun D; Xu H; Huang J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Feb; 20(2):190-194. PubMed ID: 28226354
[TBL] [Abstract][Full Text] [Related]
26. Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience.
Lubin DJ; Behrman DB; Goyal S; Magliocca K; Shi Q; Chen AY; Viswanathan K
Mod Pathol; 2023 Sep; 36(9):100235. PubMed ID: 37270155
[TBL] [Abstract][Full Text] [Related]
27. Predictive factors that influence the course of medullary thyroid carcinoma.
Pazaitou-Panayiotou K; Chrisoulidou A; Mandanas S; Tziomalos K; Doumala E; Patakiouta F
Int J Clin Oncol; 2014; 19(3):445-51. PubMed ID: 23832286
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis.
Cao ZX; Weng X; Huang JS; Long X
Updates Surg; 2022 Oct; 74(5):1551-1562. PubMed ID: 35821560
[TBL] [Abstract][Full Text] [Related]
29. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
30. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of lymph node yield and metastatic lymph node ratio in medullary thyroid carcinoma.
Leggett MD; Chen SL; Schneider PD; Martinez SR
Ann Surg Oncol; 2008 Sep; 15(9):2493-9. PubMed ID: 18594930
[TBL] [Abstract][Full Text] [Related]
32. Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer.
Adam MA; Thomas S; Roman SA; Hyslop T; Sosa JA
JAMA Surg; 2017 Sep; 152(9):869-876. PubMed ID: 28636692
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of lymph node metastasis and the eighth edition of AJCC for patients with anaplastic thyroid cancer.
Zhang H; Zhao YC; Wu Q; Wang L; Sun S
Clin Endocrinol (Oxf); 2021 Sep; 95(3):498-507. PubMed ID: 33864292
[TBL] [Abstract][Full Text] [Related]
34. Nodal disease burden and outcome of medullary thyroid carcinoma.
Moses LE; Oliver JR; Rotsides JM; Shao Q; Patel KN; Morris LGT; Givi B
Head Neck; 2021 Feb; 43(2):577-584. PubMed ID: 33107153
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Performance of Alternative Lymph Node Classification Systems for Patients with Medullary Thyroid Cancer: A Single Center Cohort Study.
Prassas D; Kounnamas A; Cupisti K; Schott M; Knoefel WT; Krieg A
Ann Surg Oncol; 2022 Apr; 29(4):2561-2569. PubMed ID: 34890024
[TBL] [Abstract][Full Text] [Related]
36. SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival.
de Vries LH; Lodewijk L; Willems SM; Dreijerink KMA; de Keizer B; van Diest PJ; Schepers A; Bonenkamp HJ; van Engen-van Grunsven IACH; Kruijff S; van Hemel BM; Links TP; Nieveen van Dijkum EJM; van Eeden S; Valk GD; Borel Rinkes IHM; Vriens MR
Endocrine; 2018 Dec; 62(3):639-647. PubMed ID: 30128959
[TBL] [Abstract][Full Text] [Related]
37. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
38. Measuring discrepancies between simple medullary and synchronous medullary/papillary thyroid carcinomas: a comparative cross-sectional study.
Zhang D; Yang M; Frattini F; Cestari A; Li K; Wang H; Chi H; Sui C; Bai K; Lan D; Dionigi G; Sun H
Front Endocrinol (Lausanne); 2023; 14():1301200. PubMed ID: 38317715
[TBL] [Abstract][Full Text] [Related]
39. Inclusion of the Number of Metastatic Lymph Nodes in the Staging System for Medullary Thyroid Cancer: Validating a Modified American Joint Committee on Cancer Tumor-Node-Metastasis Staging System.
Wang Z; Tang C; Wang Y; Yin Z; Rixiati Y
Thyroid; 2022 May; 32(5):536-543. PubMed ID: 35350868
[No Abstract] [Full Text] [Related]
40. High Ratio of Early Postoperative Calcitonin to Preoperative Calcitonin Could be a Novel Indicator of Poor Prognosis in Patients with Biochemical Incomplete Responses in Sporadic Medullary Thyroid Cancer.
Chen L; Sun W; Qian K; Guo K; Sun T; Wu YI; Wang Z
Endocr Pract; 2020 Jul; 26(7):738-747. PubMed ID: 33471642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
